

## Annex A: AVMA Base Proposal – updated key terms

This Annex provides an **updated overview** of key terms of the AVMA approved by the Gavi Board (Board-2023-Mtg-04-Doc 10b - Annex A). Updates are shown **in bold underline** and primarily represent tighter definitions and an update to eligibility criteria.

Design element	Proposal
Size	Funding requirement of US\$ 750-1,000 million – with the upper end of the range set to accommodate an ambitious outcome for African products in terms of number of incentivised manufacturers and their commercial volumes
Scope	All Gavi Alliance supported vaccines (with differences in payments, see “Incentives”), fill & finish-only (i.e. drug product), and “end-to-end” drug substance + drug product.
Duration	To be launched in <b><u>June</u></b> 2024 with a proposed duration of 10 years (payments can continue for a period beyond the 10-year mark, depending on tender lengths) <sup>1</sup>
Eligibility	<p><b><u>Vaccine Type: Qualifying Vaccine that is WHO Prequalified</u></b></p> <p><b><u>Manufacturing Type:</u></b></p> <p>i) <b><u>The Qualifying Vaccine is Fully Manufactured on the African continent;</u></b></p> <p>or</p> <p>ii) <b><u>Fill &amp; Finish of the Qualifying Vaccine is carried out in a manufacturing facility on the African continent that is Controlled by the holder of the WHO Pre-Qualification of the Qualifying Vaccine.</u></b></p>
Procurement pathway	<p>Via successful Gavi-UNICEF tenders <b><u>and fulfil all other eligibility criteria</u></b></p> <p>A potential AU pooled procurement mechanism may be accommodated in the future, <b><u>subject to determination in line with AVMA’s governance arrangements</u></b>)</p>
Incentives	<p>Structure</p> <ul style="list-style-type: none"> <li>• Milestone payment at WHO Prequalification</li> <li>• Per-dose accelerator payment, paid per dose, upon delivery of UNICEF tender</li> </ul>

Priorities	<p>Platforms: mRNA &amp; Viral Vector ('rapid response platforms')</p> <p>Vaccines:</p> <ul style="list-style-type: none"> <li>• Oral Cholera Vaccine</li> <li>• Malaria</li> <li>• Measles-Rubella (MR)</li> <li>• Hexavalent (wP)</li> <li>• Yellow Fever</li> <li>• Pneumococcal (required profile: min. 13 valent)</li> <li>• Ebola (required profile: indication against 2+ Ebola species and thermostable from –20C)</li> <li>• Rotavirus (required profile: single-dose blow-fill-seal presentation)</li> </ul>
Values	<p><b>Milestone payment</b></p> <ul style="list-style-type: none"> <li>• USD 25 million: drug substance manufactured on Priority platform</li> <li>• USD 20 million: drug substance for Priority vaccine</li> <li>• USD 10 million: drug product for Priority vaccine ("fill and finish only")</li> </ul> <p><b>Accelerator payment</b></p> <ul style="list-style-type: none"> <li>• USD 0.50 per dose: drug substance manufactured on Priority platform</li> <li>• USD 0.50 per dose: drug substance for Priority vaccine</li> <li>• USD 0.40 per dose: all other Gavi-supported drug substance</li> <li>• USD 0.30 per dose: for Gavi-supported drug product (i.e., "fill and finish only") up to a cap of USD 1 per vial</li> </ul>
Caps	<p><b><u>The total disbursement (Milestone and Accelerator payments) across the entire instrument is capped at:</u></b></p> <ul style="list-style-type: none"> <li>• <b><u>Net funds raised for the AVMA initiative, after deducting operational costs<sup>5</sup></u></b></li> <li>• USD 300 million per vaccine (pathogen) category / market</li> <li>• USD 250 million for Milestone payments</li> <li>• USD 250 million for "fill and finish only"</li> <li>• The total disbursement (Milestone and Accelerator payments) per manufacturer is capped at:</li> <li>• USD 250 million, of which, USD 50 million for "fill and finish only"</li> </ul>

1. AVMA disbursement will continue until delivery of all doses from tenders that were awarded within the 10-year timespan (subject to Caps). Tenders awarded within the 10-years may extend beyond that timespan, doses from which that are delivered will receive payment

2. The process of filling vials (or equivalent final container) with formulated drug substance with or without subsequent intermediate and final packaging

3. The process of manufacturing every constituent antigen of a vaccine

4. Manufacturers undertaking both drug substance and fill and finish steps under a tender award will receive only the drug substance per delivered dose Accelerator payment for that tender. Manufacturers obtaining PQ for Priority platforms and vaccines would be in-principle eligible for a Milestone payment ahead of any engagement in the Gavi-UNICEF tender process. Eligibility is subject to conditions specified in the detailed term sheet in Appendix 1 Framework Report

5. Operating costs to be estimated by end of 2024, as determined by operating design elements

The AVMA Term Sheet is not a comprehensive description of all aspects of AVMA and a manufacturer's ability to receive any payment of incentives under AVMA is subject to contract. The publishing of the AVMA Term Sheet by Gavi is not a commitment to enter into any transaction, contractual relationship or contractual document/s.